ÌÇÐÄÊÓÆµ

Amanda JF Tamman

Tamman

Amanda JF Tamman, M.Sc., PhD

Assistant Professor

Positions

Assistant Professor
ÌÇÐÄÊÓÆµ of Medicine
Houston, Texas, United States

Education

PhD from St. John's University
07/2022 - Queens, NY
Clinical Psychology (Child Track)
MSc from University College London/Yale Child Study Center Joint Program
05/2016 - London, United Kingdom
Developmental Neuroscience and Psychopathology
BSc from University College London
05/2014 - London, United Kingdom
Psychology

Honors & Awards

New Investigator Award
American Society of Clinical Psychopharmacology (05/2022)
Paul Baer Research Award
Research Award for best research produced among clinical psychology interns
ÌÇÐÄÊÓÆµ Medicine
Alies Muskin Career Development Leadership Program (CDLP)
Anxiety and Depression Association of America (04/2023)
Travel Award
American College for Neuropsychopharmacology (07/2023)

Professional Interests

  • Developmental Psychopathology
  • Childhood Maltreatment
  • PTSD
  • Trauma
  • Psychotherapeutics

Professional Statement

Dr. Amanda Tamman is an Assistant Professor in the Department of Psychiatry & Behavioral Sciences at ÌÇÐÄÊÓÆµ of Medicine. She aspires to improve understanding the neural ‘imprints’ left by stress and trauma to best target treatment of psychiatric disorders. Her unique viewpoint integrates interdisciplinary genetic, neural, and relational fields to understand psychiatric disorders, rather than examining these etiological factors in isolation. She gained this viewpoint with training in Developmental Neuroscience and Psychopathology, a joint MSc program at University College London and Yale Child Study Center that draws on multiple perspectives in psychiatry with an emphasis on neuroscience. Amanda’s work has two aims. First, she focuses on identifying the interaction between fMRI, neurophysiological, genetic, and behavioral factors in understanding trauma-related psychiatric disorders. Second, she aims to use this knowledge to develop and test novel treatments for stress-related disorders and potential mechanisms of their effects. This includes endeavors to examine the effect of psychedelic agents on genetic markers of aging and inflammation, and the effects of psychedelic agents on relational factors such as interpersonal skills in work funded by the American Foundation of Suicide Prevention and AIM Youth Mental Health.

Selected Publications

  • Tamman, A. J., Wendt F.R., Pathak, G.A., Krystal, J.H., Southwick, S.M., Sippel, L.M.,... & Pietrzak, R. H.. " Attachment style moderates polygenic risk for posttraumatic stress in U.S. military veterans: A 7-year, nationally representative, prospective cohort.. " Biological Psychiatry. 2022 ;
  • Tamman, A. J., Sippel, L. M., Han, S., Polimanti, R., Krystal, J. H., Southwick, S. M., ... & Pietrzak, R. H. " Attachment style moderates polygenic risk for PTSD in U.S. military veterans: Results from the National Health and Resilience in Veterans Study.. " Biological Psychiatry. 2021 ;
  • • Tamman, A. J., Nagamatsu, S., Krystal, J. H., Gelernter, J., Montalvo-Ortiz, J., & Pietrzak, R. H.. " Psychosocial factors associated with accelerated GrimAge in male U.S. military veterans.. " Am J Geriatr Psych. 2022 ;
  • Tamman, A. J., Anand, A., & Mathew, S.J. (2022).. " A comparison of the safety, feasibility, and tolerability of ECT and ketamine for treatment-resistant depression.. " Expert Opinion on Drug Safety.. 2022 ;

Funding

Effects of Psilocybin Assisted Therapy on Mentalizing
(10/01/2023 - 10/01/2025)
American Foundation for Suicide Prevention
Psilocybin-assisted therapy (PAT) shows potential for addressing suicide deaths among US veterans but requires testing in patients with low-severity suicidal thoughts to mitigate risk. We will test the effect of PAT on mild suicidal thoughts and behaviors using an existing clinical trial for veterans with PTSD, a high-risk for suicide group. Participants will undergo pre- and post-PAT assessments, including brain scans and social tasks associated with suicidal thoughts and PTSD to identify potential mechanisms for therapeutic effects.
Psilocybin and accelerated GrimAge and DNAmTL in young adults with stress-related disorders.
(10/01/2023 - 10/01/2024)
AIM Youth Mental Health
This AIM funded research will be able to study how a novel treatment for stress-related disorders may impact genetic markers of physical aging, with potentially profound implications for alleviating the physical health burden associated with stress-related disorders in this at-risk group

to edit your profile